NY S06736

Requires New York Medicaid to cover wearable medical devices that deliver low-intensity, alternating electric fields directly to tumor sites to treat glioblastoma and other cancers

Coverage must align with FDA-approved or cleared device indications

Coverage criteria include Centers for Medicare and Medicaid Services national coverage determinations and Medicare administrative contractor local coverage determinations

Nationally recognized clinical practice guidelines from organizations like the National Comprehensive Cancer Network or American Society of Clinical Oncology will guide coverage decisions

Takes effect on April 1st following enactment